X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7501) 7501
Magazine Article (43) 43
Book Chapter (31) 31
Newsletter (28) 28
Reference (10) 10
Newspaper Article (5) 5
Book Review (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Government Document (2) 2
Web Resource (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6613) 6613
thalidomide - therapeutic use (3993) 3993
thalidomide (3485) 3485
male (3256) 3256
female (3019) 3019
middle aged (2476) 2476
thalidomide - analogs & derivatives (2364) 2364
oncology (2214) 2214
multiple myeloma - drug therapy (2190) 2190
aged (2175) 2175
hematology (2069) 2069
adult (1857) 1857
treatment outcome (1739) 1739
multiple myeloma (1731) 1731
antineoplastic combined chemotherapy protocols - therapeutic use (1611) 1611
thalidomide - administration & dosage (1610) 1610
thalidomide - adverse effects (1384) 1384
bortezomib (1339) 1339
lenalidomide (1288) 1288
antineoplastic agents - therapeutic use (1219) 1219
therapy (1126) 1126
animals (892) 892
aged, 80 and over (846) 846
angiogenesis inhibitors - therapeutic use (827) 827
dexamethasone (803) 803
chemotherapy (802) 802
care and treatment (800) 800
cancer (779) 779
immunosuppressive agents - therapeutic use (778) 778
stem-cell transplantation (759) 759
dexamethasone - administration & dosage (721) 721
thalidomide - pharmacology (672) 672
survival (663) 663
pharmacology & pharmacy (656) 656
drug therapy (590) 590
prognosis (579) 579
recurrence (572) 572
multiple myeloma - pathology (563) 563
multiple myeloma - therapy (554) 554
multiple myeloma - mortality (531) 531
antineoplastic combined chemotherapy protocols - adverse effects (522) 522
transplantation (519) 519
multiple-myeloma (512) 512
medicine & public health (507) 507
angiogenesis (478) 478
immunologic factors - therapeutic use (462) 462
research (462) 462
clinical trials as topic (461) 461
disease-free survival (458) 458
retrospective studies (434) 434
hematology, oncology and palliative medicine (409) 409
remission induction (406) 406
survival analysis (394) 394
dermatology (386) 386
analysis (385) 385
dexamethasone - therapeutic use (381) 381
drug therapy, combination (381) 381
medicine, general & internal (381) 381
mice (381) 381
boronic acids - therapeutic use (380) 380
pyrazines - therapeutic use (380) 380
multiple myeloma - diagnosis (376) 376
health aspects (373) 373
follow-up studies (365) 365
disease progression (361) 361
transplantation, autologous (360) 360
trial (360) 360
melphalan (357) 357
risk factors (351) 351
boronic acids - administration & dosage (350) 350
combination (349) 349
pyrazines - administration & dosage (349) 349
combined modality therapy (347) 347
antineoplastic agents - adverse effects (341) 341
immunology (341) 341
abridged index medicus (333) 333
survival rate (330) 330
efficacy (328) 328
dose-response relationship, drug (327) 327
clinical trials (321) 321
plus dexamethasone (320) 320
necrosis-factor-alpha (318) 318
multiple myeloma - complications (313) 313
stem cell transplantation (305) 305
elderly-patients (304) 304
hematopoietic stem cell transplantation (304) 304
dosage and administration (302) 302
myelodysplastic syndromes - drug therapy (301) 301
prednisone (300) 300
stem cells (295) 295
myeloma (294) 294
time factors (290) 290
diagnosis (289) 289
expression (288) 288
adolescent (283) 283
drug administration schedule (276) 276
patients (276) 276
antineoplastic combined chemotherapy protocols - administration & dosage (266) 266
antibodies, monoclonal - therapeutic use (260) 260
cells (257) 257
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7110) 7110
French (146) 146
Japanese (133) 133
German (82) 82
Chinese (70) 70
Spanish (57) 57
Czech (22) 22
Portuguese (18) 18
Polish (17) 17
Italian (13) 13
Dutch (10) 10
Danish (7) 7
Hebrew (6) 6
Swedish (4) 4
Hungarian (3) 3
Ukrainian (3) 3
Finnish (2) 2
Korean (2) 2
Russian (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
2005, Volume 6, Issue 2, 11
.... Since there are almost no randomized, controlled, double-blind studies comparing the use of various therapeutic agents in this condition, treatment decisions still rely heavily on individual clinicians experience... 
Methotrexate, therapeutic use | Mitomycin, therapeutic use | Tetracyclines, therapeutic use | Sulfasalazine, therapeutic use | Tacrolimus, therapeutic use | Nicotinamide, therapeutic use | Cyclophosphamide, therapeutic use | Mycophenolate mofetil, therapeutic use | Pemphigoid, treatment | Calcineurin inhibitors, therapeutic use | Azathioprine, therapeutic use | Leflunomide, therapeutic use | Immunoglobulins, therapeutic use | Interferon alpha 2b, therapeutic use | Corticosteroids, therapeutic use | Sulfapyridine, therapeutic use | Sulfamethoxypyridazine, therapeutic use | Thalidomide, therapeutic use | Ciclosporin, therapeutic use | Prednisone, therapeutic use | Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | PLASMA-EXCHANGE | IMMUNOSUPPRESSIVE THERAPY | TOPICAL CYCLOSPORINE | MITOMYCIN-C | PASSIVE TRANSFER | INTRAVENOUS IMMUNOGLOBULIN THERAPY | SYSTEMIC CHEMOTHERAPY | THALIDOMIDE THERAPY | NECROSIS-FACTOR-ALPHA | MYCOPHENOLATE-MOFETIL | DERMATOLOGY | Calcineurin Inhibitors | Pemphigoid, Benign Mucous Membrane - therapy | Antibiotics, Antineoplastic - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Mitomycin - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Administration, Topical | Tetracyclines - therapeutic use | Plasmapheresis
Book Review
Journal Article
Journal Article
Cochrane library, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, pp. CD002954 - CD002954
Background Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease... 
antimalarial therapy | M. CONNECTIVE TISSUE AND IMMUNOBULLOUS AND RELATED | photoprotection | Treatment Outcome | Hydrocortisone | topical and intralesional (injected) corticosteroids | Dermatologic Agents | Skin disorders | Randomized Controlled Trials as Topic | Calcineurin Inhibitors | Fluocinonide | Connective tissue disorders & immunobullous | Acitretin | Hydroxychloroquine | Lupus Erythematosus, Discoid | Tacrolimus | thalidomide | M0 Lupus erythematosus | Lupus erythematosus | Albuterol | Medicine General & Introductory Medical Sciences | systemic corticosteroids | CUTANEOUS LUPUS | MULTICENTER | EFFICACY | SAFETY | Humans | Acitretin [therapeutic use] | Lupus Erythematosus, Discoid [drug therapy] | DISEASE AREA | THALIDOMIDE | CHLOROQUINE | Fluocinonide [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Hydroxychloroquine [therapeutic use] | DOUBLE-BLIND | TOPICAL CALCINEURIN INHIBITORS | TACROLIMUS | Dermatologic Agents [therapeutic use] | Hydrocortisone [therapeutic use] | Hydroxychloroquine - therapeutic use | Fluocinonide - therapeutic use | Lupus Erythematosus, Discoid - drug therapy | Hydrocortisone - therapeutic use | Dermatologic Agents - therapeutic use | Tacrolimus - analogs & derivatives | Dermatologic Agents - adverse effects | Tacrolimus - therapeutic use | Calcineurin Inhibitors - therapeutic use | Albuterol - therapeutic use | Acitretin - therapeutic use | Acitretin - adverse effects | Index Medicus
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2015, Volume 15, Issue 6, pp. 314 - 322
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2007, Volume 56, Issue 1, pp. 69 - 83
... vulnerable to treatment by targeted therapy. This article reviews both standard and newer therapeutic options for cutaneous sarcoidosis. 
Dermatology | TUMOR-NECROSIS-FACTOR | LOW-DOSE METHOTREXATE | IN-VITRO | GRANULOMA-FORMATION | FACTOR-ALPHA PRODUCTION | LUPUS-PERNIO | TH2 CYTOKINES | PULMONARY SARCOIDOSIS | ALVEOLAR MACROPHAGES | TNF-ALPHA | DERMATOLOGY | Abnormalities, Drug-Induced - prevention & control | Chlorambucil - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Laser Therapy | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Methotrexate - therapeutic use | Skin Diseases - pathology | Adrenal Cortex Hormones - therapeutic use | Th1 Cells - immunology | Pentoxifylline - therapeutic use | Contraindications | Infliximab | Sarcoidosis - immunology | Anti-Inflammatory Agents - therapeutic use | Female | Pentoxifylline - pharmacology | Drug Therapy, Combination | Th1 Cells - drug effects | Sarcoidosis - drug therapy | Skin Diseases - drug therapy | Skin Diseases - immunology | Antimalarials - therapeutic use | Sarcoidosis - etiology | Pregnancy Complications - drug therapy | Pregnancy | Skin Diseases - etiology | Cyclosporine - therapeutic use | Allopurinol - therapeutic use | Models, Immunological | Animals | Melatonin - therapeutic use | Antigen Presentation - drug effects | Cytokines - antagonists & inhibitors | Isoxazoles - therapeutic use | Thalidomide - therapeutic use | Tetracyclines - therapeutic use | Pregnancy Complications - immunology | Sarcoidosis - pathology
Journal Article
Cancer cell, ISSN 1535-6108, 2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis
Journal Article
Journal Article